Market Place
Sourcing Support
Athenex files for bankruptcy, seeks buyer for cell therapy unit
15 May 2023 //
FIERCE BIOTECH
Drugmaker Athenex voluntarily files for U.S. Chapter 11 proceedings
14 May 2023 //
REUTERS
Pine Pharmaceuticals Assumes Athenex`s 503B Business, Preserving Over 50 Jobs,
03 May 2023 //
BUSINESSWIRE
Athenex`s cash dries up as it faces clinical hold, creditors
21 Mar 2023 //
FIERCE BIOTECH
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results
20 Mar 2023 //
GLOBENEWSWIRE
Athenex Announces a Reverse Stock Split
14 Feb 2023 //
GLOBENEWSWIRE
Athenex to exit drug compounding business and axe 92 employees at NY plant
04 Jan 2023 //
ENDPTS
Athenex Announces Quantum Leap Collaborative Reports +ve Trial Result of I-SPY2
20 Dec 2022 //
GLOBENEWSWIRE
Athenex Exits 503B Sterile Compounding Business
16 Dec 2022 //
GLOBENEWSWIRE
Athenex Announces Positive Results of Special Stockholder Meeting
22 Nov 2022 //
GLOBENEWSWIRE
Athenex Announces Closing of the Sale of its China API Business
21 Nov 2022 //
GLOBENEWSWIRE
Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference
08 Nov 2022 //
GLOBENEWSWIRE
Athenex Provides Third Quarter 2022 Financial Results and Business Update
03 Nov 2022 //
GLOBENEWSWIRE
Athenex Announces Receipt of Positive Nasdaq Listing Determination
03 Nov 2022 //
GLOBENEWSWIRE
Athenex to Provide Corporate and Financial Update for the Third Quarter 2022
24 Oct 2022 //
GLOBENEWSWIRE
Athenex Files Definitive Proxy Statement for Special Stockholder Meeting
11 Oct 2022 //
GLOBENEWSWIRE
Athenex to Participate in the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock
11 Aug 2022 //
GLOBENEWSWIRE
Athenex, Inc. Announces Proposed Underwritten Public Offering
10 Aug 2022 //
GLOBENEWSWIRE
Intas & Dr Reddy`s in race with PEs to buy US` Athenex
05 Aug 2022 //
ECONOMIC TIMES
Athenex Provides Second Quarter 2022 Financial Results and Business Update
28 Jul 2022 //
GLOBENEWSWIRE
Athenex to publish Data from PIII Study Comparing Oral Paclitaxel + Encequidar
25 Jul 2022 //
GLOBENEWSWIRE
Athenex to Provide Corporate and Financial Update for the 2Q 2022
21 Jul 2022 //
GLOBENEWSWIRE
Athenex Enters Agreement to Sell its China API Business to TiHe Capital
11 Jul 2022 //
GLOBENEWSWIRE
Athenex to Participate in Truist Securities Cell Therapy Symposium
23 Jun 2022 //
GLOBENEWSWIRE
Athenex Announces Sale of Revenues from Royalty & Milestone Interests in Klisyri
22 Jun 2022 //
GLOBENEWSWIRE
Athenex Collaborates with Merck to Evaluate Oraxol plus KEYTRUDA in NSCLC
16 May 2022 //
GLOBENEWSWIRE
Athenex Provides First Quarter 2022 Financial Results and Business Update
10 May 2022 //
GLOBENEWSWIRE
Athenex, TCCC, CCGT at Baylor College of Medicine to Present PI Data for KUR-501
02 May 2022 //
GLOBENEWSWIRE
Athenex to Provide Corporate and Financial Update for the First Quarter 2022
29 Apr 2022 //
GLOBENEWSWIRE
Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502
25 Apr 2022 //
GLOBENEWSWIRE
Enforcement Report - Week of March 30, 2022
30 Mar 2022 //
FDA
Busted in the wake of a CRL, Athenex brings out budget axe after `going concern`
18 Mar 2022 //
ENDPTS
Athenex Provides Q4 and FY 2021 Financial Results
16 Mar 2022 //
GLOBENEWSWIRE
CORRECTION: Athenex to report Fourth Quarter and Full Year 2021, on March 16
14 Mar 2022 //
GLOBENEWSWIRE
Athenex to Provide Corporate and Financial Update Q4 and FY 2021
07 Mar 2022 //
GLOBENEWSWIRE
ImmunityBio Acquires Athenex’s Interest in Advanced Biotech Mfg Facility
15 Feb 2022 //
BUSINESSWIRE
Athenex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
09 Feb 2022 //
GLOBENEWSWIRE
ImmunityBio Expands Manufacturing Capacity with State-of-Art Manufacturing Plant
12 Jan 2022 //
BUSINESSWIRE
Athenex to Present Subgroup Analysis from Ph3 Study of Oral Paclitaxel
22 Nov 2021 //
GLOBENEWSWIRE
Athenex Announces Exclusive License Agreement with National Cancer Institute
09 Nov 2021 //
GLOBENEWSWIRE
Athenex Presents Interim Data from Study of KUR-502 in r/r Lymphoma and Leukemia
04 Nov 2021 //
GLOBENEWSWIRE
Athenex Presents Interim Data from ANCHOR Study of KUR-502
04 Nov 2021 //
BLOOMBERG
Athenex to Provide Corporate and Financial Update for the Third Quarter 2021
22 Oct 2021 //
GLOBENEWSWIRE
Athenex and the Center for Cell and Gene Therapy Announce Allowance
18 Oct 2021 //
GLOBENEWSWIRE
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel
11 Oct 2021 //
GLOBENEWSWIRE
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study
16 Sep 2021 //
GLOBENEWSWIRE
Athenex to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 Sep 2021 //
GLOBENEWSWIRE
Athenex Provides Second Quarter 2021 Corporate and Financial Update
05 Aug 2021 //
GLOBENEWSWIRE
Athenex announces additional license agreement for Tirbanibulin
26 Jul 2021 //
GLOBENEWSWIRE
Athenex provide ]financial updates for the 2nd quarter of 2021 August 5, 2021
23 Jul 2021 //
GLOBENEWSWIRE
Athenex provide ]financial updates for the 2nd quarter of 2021 August 5, 2021
23 Jul 2021 //
GLOBENEWSWIRE
Athenex provide ]financial updates for the 2nd quarter of 2021 August 5, 2021
23 Jul 2021 //
GLOBENEWSWIRE
Athenex Provide Corporate Financial Update for the Second Quarter 2021
22 Jul 2021 //
GLOBENEWSWIRE
Athenex Provide Corporate Financial Update for the Second Quarter 2021
22 Jul 2021 //
GLOBENEWSWIRE
Athenex Provides Update Regarding Oral Paclitaxel Plus Encequidar
06 Jul 2021 //
GLOBENEWSWIRE
Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion
21 May 2021 //
GLOBENEWSWIRE
Athenex, Texas Children’s Cancer Center, the Center for Cell and Gene Therapy
17 May 2021 //
GLOBENEWSWIRE
Bouncing back from a shocking CRL, Athenex shares soar, buyout of natural killer
06 May 2021 //
ENDPTS
Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy
04 May 2021 //
GLOBENEWSWIRE
